- Home
- NMRA vs VOR Comparison
NMRA vs VOR Comparison
Compare NMRA & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- VOR
- Stock Information
- Founded
- NMRA 2019
- VOR 2015
- Country
- NMRA United States
- VOR United States
- Employees
- NMRA N/A
- VOR N/A
- Industry
- NMRA
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- VOR Health Care
- Exchange
- NMRA Nasdaq
- VOR Nasdaq
- Market Cap
- NMRA 268.5M
- VOR 261.2M
- IPO Year
- NMRA 2023
- VOR 2021
- Fundamental
- Price
- NMRA $1.62
- VOR $2.17
- Analyst Decision
- NMRA Buy
- VOR Buy
- Analyst Count
- NMRA 8
- VOR 6
- Target Price
- NMRA $7.14
- VOR $3.90
- AVG Volume (30 Days)
- NMRA 931.0K
- VOR 4.9M
- Earning Date
- NMRA 08-06-2025
- VOR 08-12-2025
- Dividend Yield
- NMRA N/A
- VOR N/A
- EPS Growth
- NMRA N/A
- VOR N/A
- EPS
- NMRA N/A
- VOR N/A
- Revenue
- NMRA N/A
- VOR N/A
- Revenue This Year
- NMRA N/A
- VOR N/A
- Revenue Next Year
- NMRA N/A
- VOR N/A
- P/E Ratio
- NMRA N/A
- VOR N/A
- Revenue Growth
- NMRA N/A
- VOR N/A
- 52 Week Low
- NMRA $0.61
- VOR $0.13
- 52 Week High
- NMRA $17.19
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- NMRA 51.72
- VOR 55.72
- Support Level
- NMRA $1.56
- VOR $1.97
- Resistance Level
- NMRA $1.78
- VOR $2.32
- Average True Range (ATR)
- NMRA 0.12
- VOR 0.18
- MACD
- NMRA -0.03
- VOR -0.02
- Stochastic Oscillator
- NMRA 58.97
- VOR 78.57
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.